AzTrials
AzTrials

Neurogenic BladderNCT01263392

Comparing Urinary Tract Infections in Children With Spina Bifida Using Two Types of Catheters for Catheterization

A study testing Intermittent catheterization in people with Neurogenic Bladder and Spina Bifida, run by University of Alberta at 4 sites in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary aim of this study was to determine if using the SpeediCath hydrophilic catheter would reduce the incidence of symptomatic urinary tract infections (UTI)in children with spina bifida who perform clean intermittent catheterization for bladder management. Read more about this study

Who is it for?
Ages 3 months to 18 yearsHealthy volunteers can take part
Conditions the study is for
Neurogenic Bladder, Spina Bifida
What is being tested?
Intermittent catheterization
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
46 participants
Where
4 sitesCanada
Study dates
Apr 2007to Jan 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 months to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • Healthy Child with spina bifida who requires clean intermittent catheterization (CIC) for ongoing bladder management.
  • Child either self catheterizes or receives catheterization by a consistent person.
  • Child/parent/caregiver able to read and understand English in order to consent to participation in the study and to respond to verbal questions about the experience and satisfaction with the catheter.

Who cannot join

  • Urethral deformities (i.e. stricture, false passage)
  • Antibiotic prophylaxis
  • Allergy to PVC product
  • Diabetes Mellitus
  • Unwilling to reuse catheters
  • History of bladder pathology (ie. tumours, calculus)
  • Surgical history of augmentation (cystoplasty, continent diversion)

Trial locations and contacts

4 sites in 1 country.

Canada4 sites
  • Alberta Children's Hospital

    Calgary, Alberta

  • University of Alberta

    Edmonton, Alberta, T6G 2G3

  • BC Children's Hospital

    Vancouver, British Columbia

  • Winnipeg Children's Hospital

    Winnipeg, Manitoba

Other trials in Canada

About this study

Official title: A Comparison of the Incidence of Symptomatic Urinary Tract Infections in Children With Spina Bifida Using Hydrophilic or Non-hydrophilic Polyvinyl Chloride Catheters for Clean Intermittent Catheterization: a Randomized Cross Over Trial

The primary aim of this study was to determine if using the SpeediCath hydrophilic catheter would reduce the incidence of symptomatic urinary tract infections (UTI)in children with spina bifida who perform clean intermittent catheterization for bladder management. The hypothesis was that the incidence of symptomatic urinary tract infections would be significantly reduced (by 25%) in users of the SpeediCath hydrophilic catheter when compared to users of a reused polyvinyl chloride (PVC) catheter. Subjects were randomly assigned to either starting the study with PVC catheter for 6 months followed by the hydrophilic catheter for 6 months or visa versa. Each subject kept a weekly diary recording urinary tract infections symptoms, hematuria determined by urine dipstick, physician visits, days of missed school and other activities. At the end of each 6 months subjects completed a questionnaire recording their comfort and satisfaction in using the PVC or hydrophilic coated catheter. 70 subjects were randomized and 46 had complete data. There were no differences in febrile UTI, antibiotic use, healthcare visits or school days missed. The incidence of self reported UTI was lower in the PVC group than the hydrophilic group. 40% of subjects indicated that the hydrophilic coated catheter was slippery and difficult to handle compared to 10% for the PVC catheter. However overall satisfaction was no different between products. The study results are consistent with the current Cochrane Review that there is a lack of evidence to state that the incidence of UTI is affected by multiuse or hydrophilic catheter use.

Read the detailed description

Intermittent catheterisation (IC) is accepted management for maintaining bladder and renal health in individuals with incomplete bladder emptying. Two common products are available for IC: polyvinyl chloride (PVC) and single use hydrophilic coated PVC. In 2004 the UK spent around £33 million on hydrophilic catheters compared to £3 million for PVC catheters. Proposed advantages of the lubricated hydrophilic catheter over PVC catheters are:

  1. lower incidence of symptomatic urinary tract infections (UTI) and
  2. lower incidence of urethral irritation, trauma and urethral strictures from repeated IC.

Complications and UTIs are costly to the individual and the system but despite over 25 RCTs on the topic, there remains a lack of evidence indicating superiority of one product over another in community dwelling IC users.

Purpose: To compare the incidence of symptomatic UTI in children with spina bifida using single use hydrophilic (SpeediCath™) or PVC catheters for IC. Secondary aims: compare differences in weekly urinalysis for blood and leukocytes; physician visits, antibiotic use, days missed of school or activities; subject and care provider satisfaction with study catheter products.

Study Design, materials and methods: Randomised crossover two arm trial at four Western Canada paediatric sites: each arm was 24 weeks of single use hydrophilic or PVC catheters cleaned with soap and water (standard of care). Symptomatic UTI defined as positive leukocytes plus > 1 fever, flank pain, increased incontinence, malaise, cloudy or odorous urine requiring antibiotic treatment. Randomisation was determined at the study centre using a computer generated list into random block sizes of 8. Subject assignments were placed in opaque envelopes and sealed. After consent was obtained the local research assistant contacted the site technician who opened the envelope and gave the assignment. Sample size: With power of 80%, an expected difference of 25% between treatment and control and α 0.05, the total sample size needed was 97 subjects, using methods for correlated binary data and repeated measures. All data was entered by an impartial technician. It was not possible to blind subjects to product. Data were analyzed using a Mixed Within-Subjects Between-Subjects Analysis of Variance where the group was defined by the catheter type on which the trial began. SPSS version 20 was used for all analyses.

Inclusion Criteria: Child with spina bifida living in the community who either self IC or received IC by a consistent person; child/parent/caregiver able to read and understand English. Exclusion criteria: Urethral deformities (i.e. stricture, false passage); antibiotic prophylaxis; allergy to PVC product; diabetes mellitus; history of bladder pathology (i.e. tumours, calculus); surgical history of augmentation (cystoplasty, continent diversion).

Results: 70 subjects were randomized; 46 had complete data over 48 weeks; 24 dropouts: hydrophilic catheter too slippery (15%); refused PVC arm because they preferred hydrophilic catheter (5%); booked for continent diversion (4%), other (8%). Mean age 10.6 (SD 6.2), 21 males and 25 females. All performed IC > 3/day: 52% self and 48% parents/ caregivers; PVC catheters were used at least 5 times. Mean total weeks of self-reported UTI was 3.6 (SD 4.7) in the hydrophilic group vs. 2.3 (SD 3.3) in the PVC group (p= <.001) but no statistical differences in weeks of febrile UTI, antibiotic use, visits to physicians, days missed from school, or microscopic haematuria (urine dip). There was a trend to fewer weeks of positive leukocytes in the hydrophilic group (Table 1).

There were no statistically significant differences in Convenience or Comfort. Ease of Handling was significantly different with 40% disliking the hydrophilic product compared to 10% for the PVC product. Fewer participants answered "yes" to "would you continue using the product" (hydrophilic vs. the PVC 65% vs. 90% respectively). However, overall satisfaction was no different between products (Table 2).

Interpretation of Results:

The study was underpowered despite major attempts at recruitment. However the findings are clinically relevant. The hydrophilic catheter was more difficult to handle and therefore less likely to be continued than the PVC multiuse product. Participants who overcame the handling issues found the product excellent. Incidence febrile UTI or of antibiotic treated UTI did not appear to be affected by single use vs. multiuse products.

Conclusions: A hydrophilic catheter does not appear to reduce febrile UTI or antibiotic use in community dwelling children using CIC. Attrition was high based on participants' lack of adjustment to the hydrophilic product and to study fatigue. The study results are consistent with the existing Cochrane Review: there is a lack of evidence to state the incidence of UTI is affected by multiuse or hydrophilic catheter use. Large multicentre trials are strongly recommended.

Table 1: Mean number of weeks (of 24) with Symptoms Hydrophilic Single Use PVC multiuse N Mean N Mean Leucocytes 50 8.46 52 10.10 Fever 50 .04 49 .06 Other Symptoms ( w no Fever) 50 3.50 49 2.22 Hematuria 50 2.64 52 3.15 Antibiotics 50 .80 49 .55 Days Missed Activities 50 .40 52 .13 Note: all comparisons p>0.05

Table 2: Overall satisfaction with catheter products Hydrophilic Single Use PVC multiuse N % Acceptable N % Acceptable Convenience 49 81.6 48 81.3 p>0.05 Comfort 48 87.5 47 95.7 p>0.05 Ease of handling 49 59.2 48 95.8 p<0.05 Would you continue to use? 49 57.1 48 91.7 p<0.05 Overall satisfaction 48 72.9 48 87.5 p>0.05

Being tested
Intermittent catheterization
Keywords
Neurogenic bladder, Spina bifida, Intermittent catheterization, Urinary tract infections
Medical subject headings
Urinary Bladder, Neurogenic, Spinal Dysraphism, Urinary Tract Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intermittent catheterizationDevice

    Also called Polyvinyl Chloride, Hydrophillic - Coloplast Speedicath catheter

    Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria \& leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.

Study groups in NCT01263392
Study groupRoleWhat they receive
Polyvinyl Chloride CatheterActive comparatorRe-use clean polyvinyl chloride catheters for intermittent catheterization of children with spina bifida.
Receives: Device: Intermittent catheterization
Hydrophilic catheterActive comparatorUse hydrophilic catheters (Speedicath) for intermittent catheterization of children with spina bifida.
Receives: Device: Intermittent catheterization

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Symptomatic urinary tract infection (UTI)

    Symptomatic urinary tract infection (UTI) as per CDC definitions

    Measured: 6 months and 6 months at crossover

Secondary outcomes (1)
  1. Subject satisfaction

    Comparative data between polyvinyl chloride (PVC) and hydrophilic catheter on convenience, comfort, ease of handling, continuing to use, and overall satisfaction recorded on validated Satisfaction Questionnaire by subject

    Measured: 6 months and 6 months at cross over

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Dec 2010 (estimated)
  2. Study startApr 2007
  3. Primary completionJan 2013
  4. Study completionJan 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
46 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01263392
Sponsor's protocol ID
Speedi 10
Status last verified
Mar 2013
First submitted
16 Dec 2010
Last updated
20 Jun 2013
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Intermittent catheterization in people with Neurogenic Bladder and Spina Bifida, run by University of Alberta at 4 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Jun 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Symptomatic urinary tract infection (UTI) (time frame: 6 months and 6 months at crossover). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jun 2013; AzTrials last refreshed its copy on 3 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in